What is HC Wainwright’s Estimate for ZVRA FY2027 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at HC Wainwright lifted their FY2027 EPS estimates for Zevra Therapeutics in a research note issued on Wednesday, November 4th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of $0.66 per share for the year, up from their previous forecast of $0.55. HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is $0.72 per share.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.14. The firm had revenue of $39.66 million during the quarter, compared to analysts’ expectations of $33.88 million. Zevra Therapeutics had a return on equity of 57.91% and a net margin of 52.80%.

Other equities analysts have also recently issued research reports about the company. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a report on Thursday, August 6th. Canaccord Genuity Group reduced their price objective on Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. Citizens Jmp lifted their target price on Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, August 6th. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Finally, UBS Group reissued a “buy” rating on shares of Zevra Therapeutics in a research note on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $27.14.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock opened at $11.17 on Thursday. Zevra Therapeutics has a fifty-two week low of $8.01 and a fifty-two week high of $15.03. The stock’s fifty day moving average price is $11.10 and its two-hundred day moving average price is $10.76. The company has a market cap of $663.27 million, a PE ratio of 9.39 and a beta of 1.01.

Insider Buying and Selling

In other news, Director Corey Watton sold 12,300 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $11.25, for a total value of $138,375.00. Following the completion of the transaction, the director directly owned 1,800 shares in the company, valued at approximately $20,250. This represents a 87.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Neil F. Mcfarlane sold 20,000 shares of the stock in a transaction on Monday, October 12th. The shares were sold at an average price of $11.25, for a total value of $225,000.00. Following the completion of the transaction, the chief executive officer owned 417,225 shares of the company’s stock, valued at $4,693,781.25. The trade was a 4.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Integrated Wealth Concepts LLC acquired a new position in Zevra Therapeutics in the 2nd quarter worth about $28,000. Fulcrum Asset Management LLP acquired a new stake in shares of Zevra Therapeutics during the third quarter valued at about $31,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Zevra Therapeutics during the third quarter valued at about $33,000. State of Alaska Department of Revenue acquired a new stake in shares of Zevra Therapeutics during the third quarter valued at about $44,000. Finally, State of Wyoming bought a new stake in shares of Zevra Therapeutics during the third quarter worth about $81,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

More Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q3 2026 revenue rose 45% year over year to $37.8 million, including $34.0 million from MIPLYFFA. Earnings also beat analyst estimates, and the company marked a fourth consecutive quarterly earnings beat. Zevra Q3 financial results and corporate update Zevra beats Q3 estimates for fourth straight quarter
• Positive Sentiment: Zevra expects to file a supplemental new drug application for MIPLYFFA in Q1 2027, a potential future growth opportunity. Zevra anticipates filing MIPLYFFA sNDA in Q1 2027
• Neutral Sentiment: A European CHMP opinion on MIPLYFFA remains expected in Q4; the regulatory outcome is still pending. Regulatory timeline update

About Zevra Therapeutics

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.